medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Transcriptional survey of peripheral blood links lower oxygen saturation
during sleep with reduced expressions of CD1D and RAB20 that is reversed
by CPAP therapy
Authors: Tamar Sofer1,2,3,*, ‚Ä†, Ruitong Li2, ‚Ä†, Roby Joehanes4,5, Honghuang Lin4,6, Adam C.
Gower7, Heming Wang1,2, Nuzulul Kurniansyah2, Brian E. Cade1,2, Jiwon Lee2, Stephanie
Williams2, Reena Mehra8, Sanjay R. Patel9, Stuart F. Quan1,2, Yongmei Liu10, Jerome I. Rotter11,
Stephen S. Rich12, Avrum Spira13, Daniel Levy4, Sina A. Gharib14,‚Ä°, Susan Redline1,2,14,‚Ä°, Daniel
J. Gottlieb1,2,16,‚Ä°
Affiliations:
1

Division of Sleep Medicine, Harvard Medical School, Boston, MA, USA.

2

Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's
Hospital, Boston, MA, USA.
3

Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.

4

The Population Sciences Branch of the National Heart, Lung and Blood Institute, Bethesda,
MD, USA and the Framingham Heart Study, Framingham, MA, USA.
5

Hebrew SeniorLife, Harvard Medical School, Boston, MA, USA.

6

Department of Medicine, Boston University School of Medicine, Boston, MA, USA.

7

Clinical and Translational Science Institute, Boston University School of Medicine, Boston,
USA.
8

Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA.

9

Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh,
Pittsburgh, PA, USA.
10

Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

11

The Institute for Translational Genomics and Population Sciences, Departments of Pediatrics
and Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center,
Torrance, CA, USA.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

12

Center for Public Health Genomics, Department of Public Health Sciences, University of
Virginia, Charlottesville, VA, USA.
13

Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.

14

Computational Medicine Core, Center for Lung Biology, University of Washington Medicine
Sleep Center, Division of Pulmonary, Critical Care, and Sleep Medicine, University of
Washington, Seattle, WA, USA.
15

Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical
Center, Boston, MA, USA.
16

VA Boston Healthcare System, Boston, MA, USA.

*To whom correspondence should be addressed: tsofer@bwh.harvard.edu, 221 Longwood Ave,
Suite 225C, Boston, MA 02115.
‚Ä†These authors equally contributed to this work.
‚Ä°

These authors equally contributed to this work.

One Sentence Summary: We studied the association of gene expression in blood with
obstructive sleep apnea traits, including oxygen saturation during sleep, and identified
mechanisms that are reversed by treatment with Continuous Positive Airway Pressure.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Abstract: Sleep Disordered Breathing (SDB) is associated with a wide range of physiological
changes due, in part, to the influence of hypoxemia during sleep. We studied gene expression in
peripheral blood mononuclear cells in association with three measures of SDB: Apnea Hypopnea
Index (AHI); average oxyhemoglobin saturation (avgO2) during sleep; and minimum
oxyhemoglobin saturation (minO2) during sleep. We performed discovery association analysis in
two community-based studies, the Framingham Offspring Study (FOS; N=571) and the MultiEthnic Study of Atherosclerosis (MESA; N = 580). An association with false discovery rate
(FDR) q < 0.05 in one study was considered ‚Äúreplicated‚Äù if a p < 0.05 was observed in the other
study. Those genes that replicated across MESA and FOS, or with FDR q < 0.05 in metaanalysis, were used for analysis of gene expression in the blood of 15 participants from the Heart
Biomarkers In Apnea Treatment (HeartBEAT) trial. HeartBEAT participants had moderate or
severe obstructive sleep apnea (OSA) and were studied pre- and post-treatment (three months)
with continuous positive airway pressure (CPAP). We also performed Gene Set Enrichment
Analysis (GSEA) on all traits and cohort analyses. Twenty-two genes were associated with SDB
traits in both MESA and FOS. Of these, lower expression of CD1D and RAB20 was associated
with lower avgO2 in MESA and FOS. CPAP treatment increased the expression of these genes
in HeartBEAT participants. Immunity and inflammation pathways were up-regulated in subjects
with lower avgO2; i.e., in those with a more severe SDB phenotype (MESA), whereas immunoinflammatory processes were down-regulated in response to CPAP treatment (HeartBEAT).

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Introduction
Sleep Disordered Breathing (SDB) is characterized by abnormal respiratory patterns during sleep
and is usually associated with impaired gas exchange. The most common type, Obstructive Sleep
Apnea (OSA), is estimated to be prevalent in 17% of women and 34% of men, aged 30-70 years
(1), and contributes significantly to the incidence and morbidity of cardio-metabolic disease,
including hypertension, stroke, heart failure, coronary artery disease, atrial fibrillation, and
diabetes (2-8). OSA is characterized by episodic complete (apneas) or partial (hypopneas)
cessation of breathing during sleep, resulting in intermittent hypercapnic hypoxemia. Hypoxemia,
particularly in the presence of hypercapnia, leads to both acute and persistent increases in
sympathetic nervous system activity (9) that persists during wakefulness (10, 11) and contributes
to elevated blood pressure. The arousal that typically occurs at the termination of apneas and
hypopneas further increases sympathetic activity. Intermittent hypoxemia is also implicated in
systemic inflammation and oxidative stress that further increases risk for cardio-metabolic disease
(12-14). The molecular mechanisms underlying OSA-mediated physiological stress are not well
established, but include genetic and gene regulatory factors.

Genome-wide gene expression analysis is a powerful tool for identifying molecular mechanisms
underlying complex traits (15-17). Hypoxemia is known to influence gene expression, partly by
affecting transcription factor activation, including both HIF-1Œ± and NF-Œ∫B (18); therefore, the
impact of OSA on gene expression, and particularly that of inflammatory genes, is anticipated.
Although gene expression profiles may differ across tissues (19), intermittent hypoxemia has been
shown to affect gene expression in peripheral blood mononuclear cells of healthy volunteers (20).
Currently, studies of gene expression in OSA (or SDB) are limited. Five studies ranging in size

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

from 18 to 48 individuals have evaluated the impact of OSA on gene expression in peripheral
blood monocytes or total leukocytes, either cross-sectionally in comparison to those without OSA
(20-22), or pre- and post-treatment with continuous positive airway pressure (CPAP) (23, 24), the
most common therapy for OSA. These small studies had limited power to detect significant
expression differences (or changes with treatment) in individual genes, although pathway analysis
suggested possible involvement of inflammatory, cell cycle, and neoplastic pathways (23). In
addition to their small sample size, some studies targeted a specific patient population (e.g.,
children) (22) or a limited set of genes (21), and generally focused on dichotomized
(presence/absence) OSA traits. Larger sample sizes and analysis of quantitative OSA trait values
are important to increase statistical power, enhance generalizability of the results, and provide
insight into which aspects of OSA may be responsible for observed effects on gene expression.
Complementary analyses that address causality are needed to overcome confounding that may be
present in observational studies.

To address these gaps in knowledge, we conducted the largest analysis to date of genome-wide
transcriptional associations with multiple traits that characterize different aspects of SDB: the
apnea hypopnea index (AHI) as well as the average and the minimum oxyhemoglobin saturation
during sleep (avgO2 and minO2, respectively). We analyzed this large, population-based
peripheral blood transcriptomics data set in relation to SDB phenotypes using two complementary
approaches with respect to: gene-focused analysis with cross validation, and pathway-based
methods. For the gene-focused approach, we first performed a discovery association analysis of
gene expression in two population-based cohorts: the Framingham Offspring Study (FOS, (25))
and the Multi-Ethnic Study of Atherosclerosis (MESA, (26)). Second, we further evaluated genes

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

identified in the discovery study using fifteen individuals from the Heart Biomarkers in Apnea
Treatment (HeartBEAT) clinical trial (27). These subjects had moderate to severe OSA and were
adherent to CPAP for three months. In the pathway-based approach, we performed Gene Set
Enrichment Analysis (GSEA) in each of these cohorts to determine those processes that are
associated with distinct SDB traits and, in the case of HeartBEAT, we assessed the effect of OSA
therapy

in

altering

canonical

biological

pathways.

Fig. 1. Gene-based analysis workflow. This figure displays the cross-replication and metaanalysis approach for discovery of gene transcripts associated with OSA traits, and
follow-up association analysis of response to CPAP treatment in HeartBEAT.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Materials and Methods
The central study design is illustrated in Fig. 1. We start with a single-gene association discovery
step, in which we studied the association of gene-expression with SDB traits in two discovery
cohorts: the Framingham Offspring Study (FOS) and the Multi-Ethnic Study of Atherosclerosis
(MESA). First, we performed association analysis in each of FOS and MESA separately, and
tested for replication of gene expression associations in the second study (cross-replication),
following the standard in genetic analysis for replication as a gold standard for limiting false
discoveries. Then, to increase power, we meta-analyzed estimated associations across FOS and
MESA. Finally, we took genes that either cross-replicated between FOS and MESA or were

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

detected in their meta-analysis and studied where the expression of these genes responds to
CPAP treatment in the HeartBEAT clinical study.

The Multi-Ethnic Study of Atherosclerosis (MESA)
MESA is a longitudinal cohort study, established in 2000, that prospectively collected risk factors
for development of cardiovascular disease among participants in six field centers across the United
States (Baltimore City and Baltimore County, MD; Chicago, IL; Forsyth County, NC; Los Angeles
County, CA; Northern Manhattan and the Bronx, NY; and St. Paul, MN). The cohort has been
studied every few years. For the present analysis, we consider N = 619 individuals who participated
in a sleep study (28, 29) and had available gene expression data. Blood for gene expression was
drawn during the Exam 5 core examination (2010-2012) and sleep studies were conducted in an
ancillary exam (2010-2013). Blood collection and monocyte sample purification were performed
sequentially using sodium heparin-containing Vacutainer CPTTM cell separation tubes (Becton
Dickinson, Rutherford, NJ, USA) and anti-CD14-coated magnetic beads, using an AutoMACs
automated magnetic separation unit (Miltenyi Biotec, Bergisch Gladbach, Germany), as detailed
before (30). Sleep data were collected using standardized full in-home level-2 polysomnography
(Compumedics Somte Systems, Abbotsville, Australia, AU0), as described before (29). After
removal of 39 observations due to missing sleep data, we included 580 participants in the analysis:
196 African-Americans (AA), 259 European-Americans (EA) and 125 Hispanic-Europeans (HA).

Gene expression data collection and processing in MESA
Gene expression profiling in MESA was described in Liu et al (30). Briefly, peripheral blood
samples of 1,264 randomly selected MESA participants from four MESA field centers (Baltimore,

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

MD; Forsyth County, NC; New York, NY; and St Paul, MN) were obtained during the fifth
examination, and mononuclear cells were isolated with consistent purity of > 90%. Blood was
drawn in the morning following 8 hours fast. Extracted RNA that passed Quality Control (QC)
testing was reversely transcribed, amplified and subjected to global expression microarrays. Global
expression quantification was measured by Illumina HumanHT-12 v4 Expression BeadChip and
Illumina Bead Array Reader. Samples were assigned to chips via stratified random sampling to
prevent potential batch, chip, and position biases. Gene expression data underwent pre-processing,
QC, and normalization, in steps including local background correction, elimination of probes not
satisfying QC criteria, and normal-exponential convolution model. This was done using a series
of Bioconductor packages (beadarray, limma etc) and Illumina software GenomeStudio. These
steps resulted in gene expression data for 14,619 transcripts for further statistical analysis.

Association analyses in MESA
We fit linear mixed models separately in each race/ethnic group to estimate the association
between SDB exposures and gene expression markers, with a random effect for gene expression
chip. Covariates (fixed effects) were study site, residual cell contamination (Neutrophils, Natural
Killer cells, T cell, B cell), age, and sex. When the model did not converge due to null variance
component, we fit a linear regression model with original fixed effects. The regression results from
the three groups where then combined using inverse-variance fixed effects meta-analysis. In
sensitivity analysis, we also adjusted for BMI.

Framingham Offspring Study (FOS)

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

FOS, initiated in 1971, is a prospective epidemiologic study of 5,124 young adults, consisting of
offspring of the original Framingham Heart Study cohort and their recruited spouses (31). The
cohort has been examined every 4-8 years for standardized medical history, blood tests and 12lead ECG (32, 33). Of FOS participants, 699 were enrolled in the Sleep Heart Health Study
(SHHS), which was initiated with a first visit (1995 ‚Äì 1998) that included in-home level-2
polysomnography (Compumedics P-Series, Abbotsville, Australia), followed by a second visit
(2001 ‚Äì 2003), in which a subset of 385 people underwent repeat polysomnography (34, 35). At
the FOS eighth examination cycle (2005 - 2008), RNA was extracted from whole blood for gene
expression profiling (36, 37). In this manuscript, we consider 517 individuals, all EuropeanAmericans, with both gene expression and polysomnography data. To minimize the time gap
between gene expression and polysomnography measurements and maximize statistical power, the
polysomnography measurements and corresponding phenotypes were taken from the second
SHHS visit when available, and otherwise, from the first SHHS visit.

Gene expression data collection and processing in FOS
Gene expression profiling and consecutive processing for FOS cohort have been described in detail
by Joehanes et al and Lin et al (37, 38). Briefly, collected peripheral whole blood samples from
each participant were used for RNA extraction. Total RNA was then amplified, labeled, and
reversely transcribed into cDNA. The cDNA hybridization was conducted on a Human Exon 1.0
ST array. Pre-processing steps included log2 transformation, quantile normalization, and
summarization with Robust Multi-array Average method. QC steps excluded exons with low
signal to noise ratio and transcript clusters with missing matches in RefSeq transcript records. This
resulted in 17,873 distinct transcripts available for analysis. Subsequent statistical analysis was

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

adjusted for multiple batch effects and technical variables and estimated white cell counts as
described in (37).

Association analysis in FOS
We fit linear mixed models to estimate the association between SDB exposure and gene expression
markers, with a random effect accounting for familial relatedness. Covariates (fixed effects) were
estimated white blood cell counts (Neutrophils, Natural Killer cells, T cell, B cell), sex, age, and
in sensitivity analysis, BMI. Because for FOS the expression measures were taken from blood 213 years after the sleep study, it is not clear how and if time varying covariates may confound the
SDB-trait gene expression association, and we adjusted for age and BMI measures at the time of
the sleep study.

SDB phenotypes and covariates
In both discovery cohorts, we studied three quantitative measures of SDB, assessed by overnight
PSG: 1) Apnea-Hypopnea indexes (AHI), defined as the number of apneas plus hypopneas per
hour of sleep that were associated with at least 3% oxygen desaturation from the preceding
baseline; 2) Average

oxyhemoglobin saturation during sleep (avgO2); and 3) Minimum

oxyhemoglobin saturation (minO2) during sleep. Covariates included sex, age, and BMI (for
sensitivity analysis).

Cross-replication analysis
Each of MESA and FOS studies where treated as both a ‚Äúdiscovery‚Äù and a ‚Äúreplication‚Äù study. For
each discovery cohort and each of the SDB exposures, we computed FDR-adjusted p values (FDR

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

q values; (39)) across the expression transcripts. Then, we took all expression transcripts with q <
0.05 for replication in the other cohort. Replication is complicated by the fact that there are
sometimes multiple transcripts per gene, and further, MESA and FOS used different platforms, so
that gene transcripts did not necessarily match between the discovery and replication studies.
Therefore, we used an approach termed ‚Äúmany to many‚Äù (40) in which a transcript of a specific
gene in the discovery study was matched to all transcripts of the same gene in the replication study.
After matching the list of discovery transcripts with FDR q < 0.05 in one cohort to a list of
transcripts in the second cohort, a corresponding gene was replicated if one of the transcripts in
the replication study had a one-sided p value < 0.05, requiring that the direction of association be
the same as the transcript in the discovery study (41). Replicated genes were carried forward for
further analysis in the CPAP treatment cohort.

Meta-analysis of MESA and FHS
Using the same ‚Äúmany-to-many‚Äù approach described above, we matched all expression transcripts
in MESA and FOS, and performed inverse-variance fixed-effects meta-analysis for overall
exposure effect. We computed FDR-controlling qs. Genes with at least one transcript with FDRvalue < 0.05 were carried forward for further analysis in the CPAP treatment cohort.

Treatment response in a clinical cohort: the Heart Biomarker Evaluation in Apnea Treatment
(HeartBEAT) study
The Heart Biomarker Evaluation in Apnea Treatment (HeartBEAT) study is a randomized, 4-site
single-blind clinical trial that investigated the efficacy of OSA therapy in reducing cardiovascular
disease risk for patients with moderate-severe OSA (ClinicalTrials.gov NCT01086800) (27). (27).

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Of HeartBEAT participants randomized to the CPAP treatment group, a subsample of 15
individuals who were highly adherent to CPAP therapy (defined by at least 4 hours of CPAP use
per night over the 3-month intervention period) was selected for gene expression analysis.
Venipuncture was performed in the morning following an overnight fast. Venous blood was
collected in 8 mL heparinized Cell Prep Tubes containing Ficoll Hypaque (Becton Dickinson
#362753) in order to separate peripheral blood mononuclear cells. The tubes were centrifuged
fresh at room temperature for 15 minutes at 2000 G to isolate the buffy coat, which was pelleted,
resuspended in Millipore S-002-10F freezing medium, and cryopreserved at -80C. Total RNA
was extracted using Qiagen's miRNeasy Mini kit following the manufacturer's standard protocol.
Gene expression profiling was performed using the Affymetrix Human Gene 1.0 ST array in
samples collected before initiating CPAP and after three months of CPAP treatment. Raw CEL
files were normalized to produce gene-level expression values using the implementation of the
Robust Multiarray Average (RMA) in the affy Bioconductor R package (version 1.36.1) and an
Entrez Gene-specific probeset mapping from the Molecular and Behavioral Neuroscience Institute
(Brainarray) at the University of Michigan (version 16.0.0). Student's paired t test was performed
using the implementation in the multtest R package (version 2.14.0), and correction for multiple
hypothesis testing was accomplished using the Benjamini-Hochberg false discovery rate (FDR).
Analysis of the HeartBEAT microarray data was performed using the R environment for statistical
computing (version 2.15.1).

Testing of genes identified by MESA and FOS analyses
We used a statistical replication testing framework to study whether genes associated with SDB
traits respond to OSA treatment using CPAP. We calculated the mean fold change with gene

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

expression data collected post- and pre-CPAP therapy across the 15 HeartBEAT subjects. For any
given gene that was carried forward from either the cross-replication or the meta-analysis of MESA
and FOS (see Fig. 1), we computed the replication p value by applying a one-sided t-test on the
log of the estimated fold expression change. Because the replication framework, requires that
effects are consistent in their direction in the discovery and the replication stage, we defined the
direction of association between gene expression marker and OSA as positive if the mean fold
change was larger than 1 and negative otherwise. Thus, we computed one-sided p values so that a
gene could be declared as replicated in HeartBEAT only if its expression was positively associated
with more severe SDB in MESA and FOS and decreased following three months of CPAP
treatment in HeartBEAT (or vice versa). Finally, a gene was determined as responding to treatment
if its replication (one-sided) p value was < 0.05.

Gene Set Enrichment Analysis
We performed gene set enrichment analysis (GSEA, (42)) for quantitative SDB traits in each
cohort. For MESA and FOS, GSEA was applied separately for AHI, avgO2, and minO2 using
the entire gene expression profiles rank ordered based on each gene‚Äôs test statistic for the
corresponding SDB trait. For HeartBEAT, the transcriptome was rank ordered based on the
paired t statistic computed with respect to CPAP therapy. When more than one transcript was
available for a single gene (for MESA and FOS), a single transcript was selected at random. To
maximize biological relevance, we leveraged only curated pathways (Molecular Signature
Database ‚ÄúCanonical pathways‚Äù and ‚ÄúHallmark‚Äù collections, gene symbol identifiers, version
6.0) for a total of 1379 gene sets, and performed permutation analysis (n = 1000 permutations).
We used cutoff of FDR q < 0.05 to identify significantly enriched pathways. We used

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Enrichment Map (43), a plug-in application within the Cytoscape (v3.3.1) environment (44), to
develop a network-based visualization of the GSEA results.

Results
Participant Characteristics
Demographic characteristics of the discovery studies FOS and MESA and the clinical
intervention study HeartBEAT are provided in Table 1. Age and BMI were similar across
cohorts. As expected, HeartBEAT study participants, who were recruited based on a minimum
AHI of 15 events/hour, were somewhat heavier and had more severe OSA than the general
population samples of FOS, and were also almost entirely male. FOS and HeartBEAT
participants were almost all of European descent, while the MESA participants included many of
African and Hispanic/Latino ancestry. Fig. 1 summarizes the analysis workflow.

Table 1. Characteristics of participants in the MESA, FOS, and HeartBEAT studies. For
continuous variables, the table provides mean and standard deviation (in parentheses). For
categorical variables, the table provides number of participants and percent of cohort (in
parentheses). FOS characteristics are at the time of the sleep study. HeartBEAT characteristics
are prior to CPAP treatment, except for CPAP adherence, which provides the average number of
hours used by the participant per night over the three-months treatment period.
Characteristics
N

MESA

Cohort
FOS

HeartBEAT

619

517

15

68.7 (9.2)

62.21 (9.0)

65.85 (7.7)

Demographics
Age (yr)

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Characteristics
Male sex (%)

MESA

Cohort
FOS

HeartBEAT

329 (53.2)

264 (51.1)

14 (93.3)

Ethnicity (%)

-

African Americans (%)

130 (21.0)

-

-

Hispanic Americans (%)

203 (32.8)

-

-

European Americans (%)

286 (46.2)

517 (100.0)

13 (86.7)

-

-

2 (13.3)

29.81 (5.6)

29.02 (5.3)

31.45 (3.3)

avgO2 (%)

94.2 (1.8)

94.3 (2.0)

93.3 (1.7)

minO2 (%)

83.0 (7.7)

84.5 (6.2)

77.7 (7.2)

AHI (events/ hr)

19.6 (18.9)

14.4 (15.1)

36.9 (9.4)

--

--

5.7 (1.9)

Mixed (%)
BMI (kg/m2)
OSA Traits

CPAP adherence (hr/night)

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Gene-based identification of transcripts associated with SDB traits
To identify differentially expressed genes associated with SDB traits, we first performed a crossreplication analysis, in which we conducted discovery analysis in each of FOS and MESA,
followed by replication analysis in the other cohort, approach aligned with the current standards
in genetic studies considered vital to interpretation of statistically significant findings. We then
meta-analyzed the information from FOS and MESA to increase power (45).

Table 2 lists eight genes that associated with the SDB traits in the cross-replication analysis. The
expression of RAB20 was positively associated with avgO2, while expression of CDYL was
negatively associated with avgO2, in both FOS and MESA. Moreover, RAB20 expression
increased following CPAP treatment in HeartBEAT (p = 0.046). The expression of TUBB6,
INVS1ABP, MAPK1, VIM, STX2, and CRIP1 was associated with either minO2 or avgO2 in both
MESA and FOS, but their expression was unchanged following CPAP treatment in HeartBEAT.

Table 3 lists 21 genes whose expressions was associated with either AHI, avgO2, or minO2 in
the meta-analysis of FOS and MESA. Of these genes, 14 (67%) were significant only in the
meta-analysis, including CD1D, whose expression was lower in association with more severe
OSA in the discovery cohorts and significantly increased with CPAP in the HeartBEAT study (p
= 0.002). Fig. 2 provides a clustered heatmap of the effect sizes (in standard deviations) of the
identified transcripts that either cross-replicated between FOS and MESA, or were detected in
the meta-analysis for each of the SDB traits.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Fig. 2. Clustered heatmap of standardized effect sizes for the OSA-associated genes in each of
the OSA traits. For each of the genes that cross-replicated in MESA and FOS, or were
discovered in their meta-analysis, the figure displays the effect sizes per 1 standard deviation of
the trait, in the study. In MESA, effect sizes are based on the meta-analysis of the estimates in
the three race/ethnic groups. Positive (blue) effect sizes of AHI and negative (orange) effect sizes
of avgO2 and minO2 represent higher expression with more severe OSA symptoms. When
multiple probes interrogated a single gene, the figure displays only one of them, selected at
random, because the results were similar across all transcripts within each gene.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Pathway-based identification of processes altered in SDB
To gain a more comprehensive assessment of gene expression patterns of SDB-associated traits,
we complemented our gene-focused association analysis by applying Gene Set Enrichment
Analysis (GSEA) to the entire available transcriptome in each cohort. We surveyed 1,379
canonical pathways and applied a strict FDR significance threshold (FDR q < 0.05). Data file S1
provides complete results and Table S1 provides the number of significant pathways (FDR q <
0.05) in each of the analyses. Supplementary Fig. S1 visualizes all pathways with FDR q < 0.05
in one analysis and p < 0.05 in at least one other analysis.

In the FOS study, in which gene expression was assayed several years after the sleep study, heme
metabolism was strongly and significantly up-regulated with respect to SDB severity; this was
also observed in MESA, although it did not pass multiple testing correction (AHI p = 0.02;
avgO2 p = 0.002). Other pathways had less consistent patterns across analyses. In MESA, the
strongest signal was found for avgO2: 150 gene sets were significantly up-regulated (FDR
q<0.05) with low average oxyhemoglobin saturation (i.e., with worse SDB). A visual summary
of this result is depicted in Fig. 3, where network analysis was used to link related gene sets into
larger modules comprised of functionally similar processes, in particular those related to
immunity and inflammation or development and remodeling. In the HeartBEAT cohort, we
found that pathways involved in immunity and inflammation, transcription and cell cycle, and
circadian rhythms were down-regulated following CPAP therapy, whereas gene sets related to
oxidative phosphorylation and metabolism were up-regulated (Fig. 4). Taken together, our
pathway analyses across multiple cohorts suggested that immuno-inflammatory processes are

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

activated in individuals with low avgO2 and, importantly, effective treatment of OSA with
CPAP moderates this pro-inflammatory signal.
Discussion
We performed a comprehensive study of the association of SDB traits with genome-wide gene
expression in peripheral blood. We combined two large population-based studies, FOS and
MESA, to study the associations of three continuous measures of SDB in the general population,
and we also compared gene expressions before and after CPAP treatment in a subset of
individuals from the HeartBEAT clinical trial who had moderate to severe OSA and were
adherent to treatment. We identified 22 genes whose expressions were associated with SDB traits
in either cross-replication or meta-analysis of FOS and MESA. Most of these differentially
expressed genes were associated with measures of hypoxemia: avgO2 and minO2. While these
measures of hypoxemia may be influenced by conditions other than SDB, two of these genes,
CD1D and RAB20, showed evidence of change with OSA treatment in the expected directions;
both were expressed at lower levels in individuals with more severe SDB in FOS and MESA,
and their expression increased significantly in HeartBEAT patients following treatment with
CPAP, suggesting that OSA was the cause of their differential expression.

The RAB20 gene encodes the Ras-related protein Rab20, a member of the Rab family of small
GTPAses. Expression of RAB20 is regulated by Hypoxia-Inducible transcription factor (HIF-1Œ±)
(46), a protein whose expression responds to changes in tissue oxygen tension, and enhances
oxygen availability and reduces oxygen demand in a hypoxic microenvironment (47). In our
analysis, more severe SDB (higher AHI, lower minO2, and avgO2) was associated with lower
expression of RAB20. Impaired RAB20 expression in human skeletal muscle is associated with

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

impaired skeletal muscle glucose uptake and reduced total body insulin sensitivity (47).
Reduced insulin sensitivity is a common pathophysiological finding in SDB (48, 49) and can be
induced by as little as 8 hours of exposure to intermittent hypoxia (50, 51). Recent animal data
also indicate that RAB20 is a negative regulator of neurite outgrowth, and thus may influence
neuronal network development, potentially influencing brain development (52). The lower
RAB20 expression in association with SDB severity is somewhat surprising, as hypoxemia is
reportedly associated with HIF-1-mediated up-regulation of RAB20 expression (34,(46). There
was only a very weak evidence for association of HIF-1ùõº expression with SDB traits in our
analysis, however, possibly reflecting the complexity of pathways that regulate HIF-1, including
both hypoxia and redox-sensitive pathways, as well as the predominantly post-transcriptional
mechanisms regulating HIF-1 signaling (53). That CPAP treatment was associated with
increased RAB20 expression in HeartBEAT subjects implies that OSA was the cause of reduced
RAB20 expression in the cross-sectional analysis, and suggests a mechanism whereby CPAP
treatment may improve glucose metabolism in OSA patients.

The CDID gene encodes the CD1D antigen, an MHC class I-like molecule expressed on both
myeloid and lymphoid cells that binds glycolipids and presents them to T cell receptors on
natural killer T cells (54, 55). It is possible that reduction in CD1D antigen, potentially
associated with the observed reduction in its expression, may contribute to impaired immune
function that has been observed in individuals with OSA (56, 57). CD1D expression was
reported to be regulated by retinoic acid (58) in mononuclear cells. In addition, the retinoic acid
pathway was significantly down-regulated in lower avgO2 in MESA, and up-regulated in
response to CPAP treatment in HeartBEAT (Data File S1), suggesting a role for retinoic acid in

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

mediating reduced CD1D expression in SDB. It has also been reported that natural killer (NK) T
cells have impaired maturation and cytotoxicity in untreated OSA patients, and that this
immunosuppressive phenotype was correlated with severity of hypoxemia (59). Given the
apparent importance of NK cell activity to immunosurveillance of human cancer (60), CD1Dmediated impairment in natural killer cell function may be implicated in the increased cancer risk
in individuals with OSA (61, 62) as well as the increased tumor implantation and growth in
animal models of intermittent hypoxia (63, 64).

Other genes identified by the FOS and MESA analysis that did not demonstrate a response to
CPAP treatment in HeartBEAT subjects include MAPK1, involved in the HIF-1ùõº response to
hypoxia (65), and CTNNA1, that encodes a protein shown to respond to chronic intermittent
hypoxia in a mouse study of transcription in cardiac rhythm genetic networks (66). Two related
genes were up-regulated under lower oxygen saturation: annexin A2 (ANXA2) and S100 Calcium
Binding Protein A10 (S100A10). These genes code proteins that interact with each other (67) and
both were shown to contribute to pulmonary microvascular integrity by preventing vascular leak
during alveolar hypoxia in mice (68). Since the expression of these genes did not respond to
CPAP therapy, they may indicate persistent alterations in transcriptional response as a result of
chronic OSA.

Hypoxemia is known to influence the expression of a wide array of genes and prior studies have
demonstrated many more genes are up-regulated than down-regulated in response to
experimental sustained or intermittent hypoxemia (50). Consistent with this finding, we
observed many more pathways up-regulated than down-regulated in association with increased

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

severity of SDB traits such as low avgO2. Gene set enrichment analysis demonstrated upregulation of heme metabolic pathways across FOS and MESA cohorts with more severe SDB
symptoms. Previous experiments showed that subjecting cells to hypoxia up-regulates the
expression of several proteins involved in iron/heme metabolisms, including transferrin (69),
transferrin receptor (70), ceruloplasmin (71), and erythroid 5-aminolevulinate synthase (72) in
order to increase erythropoiesis and hematopoietic iron supply. Our previous genetic association
analysis identified variants eQTL for ferrochelatase (FECH), the terminal enzyme in heme
biosynthesis, associated with SDB traits (73), suggesting a possible bidirectional association
between SDB and heme metabolism pathways.

A key finding of our study is that in a large, ethnically diverse subject cohort to date (MESA),
was demonstrating that SDB is associated with up-regulation of pathways involved in immune
function and inflammation (Fig. 3). Critically, we found that this immuno-inflammatory signal
was down-regulated in the HeartBEAT study patients following CPAP treatment (Fig. 4),
providing the first transcriptome-wide evidence that is consistent with a reversal of known proinflammatory markers of OSA with effective therapy (74). Another large biological module
emerging from pathway analysis of the MESA cohort was up-regulation of gene sets involved in
development and remodeling. This finding is supportive of the growing evidence based on
animal models and human data that OSA and nocturnal hypoxemia are associated with aberrant
cardiovascular remodeling (75-77). In the HeartBEAT cohort, we also observed down-regulation
of pathways involved in cancer and cell cycle following resolution of OSA and nocturnal
hypoxemia with CPAP therapy. Although many cell types, including lymphocytes, may undergo
cell cycle arrest in response to hypoxia (78, 79), our findings are consistent with recent work

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

supporting down-regulation of neoplastic programs after CPAP (23) and the potentially
increased risk of cancer associated with OSA and nocturnal hypoxemia (80, 81).

In this work, we utilized data from three different studies to identify genes and gene sets that
show expression levels that vary with SDB traits, then explored which expression signals change
with OSA treatment. These studies differed in designs and populations. Notably, despite
differences in the temporal associations between the sleep studies and gene expression assays (in
MESA the sleep study was performed during the year following the blood draw while in FOS,
the sleep study was performed between 13 to 2 years prior to the blood draw), and racial/ethnic
composition of the samples, we observed consistent associations for 22 genes in FOS and
MESA. The comparability of findings despite variations in the timing between the sleep
phenotyping and blood draws may reflect that relative stability of SDB traits over approximately
5 years (82). In the Supplementary Materials, we further report look-ups of previously-reported
genes associated with OSA and with CPAP treatment.

These analyses in the observational MESA and FOS studies cannot distinguish between effects
of OSA on gene expression and effects of gene expression as a cause of OSA. As the
associations observed are strongest for measures of sleep-related hypoxemia, rather than the
AHI, these analyses are also unable to distinguish effects of OSA from effects of hypoxemia that
may be due to underlying pulmonary disease. The data from HeartBEAT study showing that the
reduced gene expression of CD1D and RAB20 seen in the cohort studies was reversed by CPAP
treatment is strong evidence that OSA is the cause of the reduced expression of these genes.
However, the HeartBEAT sample was small and the lack of significant change in gene

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

expression for the other signals that were identified in the FOS and MESA discovery step does
not exclude an etiological role of those genes in OSA-related regulatory pathways.

SDB is strongly associated with BMI (83), and it is challenging to disentangle the effect of SDB
from that of BMI. In a sensitivity analysis (Tables S2 and S3), most of the associations become
slightly weaker after adjustment for BMI; however, BMI directly influences SDB by altering
airway collapsibility, and it is therefore not clear that adjustment for BMI results in a less rather
than a more confounded effect estimate. The response to CPAP therapy of CD1D and RAB20
indicates that the expression changes identified for these genes is due to OSA and not obesity.

In summary, we report the largest gene expression analysis of SDB traits to date. While precise
measures of SDB are challenging to obtain in large-scale cohorts, we leveraged the availability
of population-based studies that performed in-home polysomnography and combined our
transcriptional analysis of these cohorts with a clinical trial for better control of confounding and
confirmation of expression changes with treatment. Using a gene-focused discovery and
validation methodology, we identified CD1D and RAB20 as being key down-regulated genes in
SDB whose expression responded to CPAP treatment. A complementary pathway-based
approach revealed that SDB severity is associated with alteration of distinct peripheral blood
programs including up-regulation of immuno-inflammatory signals that were reversed with
effective CPAP therapy. Collectively, our study provides a framework to investigate the
transcriptional consequences of SDB traits in multi-cohort datasets and identify putative
candidate genes and processes driving this response.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Supplementary Materials include:
Supplementary Methods
Fig. S1. Overlap between enriched gene sets at the p < 0.05 level.
Table S1. Number of enriched gene sets in each of the cohort and trait analyses.
Table S2. Results from sensitivity analysis in MESA, for transcripts reported in Table 2.
Table S3. Results from sensitivity analysis in MESA, for transcripts reported in Table 3.
Data file S1. Complete results from Gene Set Enrichment Analyses.
Data file S2. Gene expression associations of previously-reported genes.
Data file S3. Complete results from transcriptome-wide association analyses with SDB traits in
MESA.
Data file S4. Complete results from transcriptome-wide association analyses with SDB traits in
FOS.
Data file S5. Complete results from the meta-analyses of transcriptome-wide association
analyses in MESA and FOS.
Data file S6. Complete results from transcriptome-wide association analysis with CPAP
treatment in HeartBEAT.

References:
1.

Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of

sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-14.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

2.

Logan AG, Tkacova R, Perlikowski SM, Leung RS, Tisler A, Floras JS, et al. Refractory

hypertension and sleep apnoea: effect of CPAP on blood pressure and baroreflex. Eur Respir J.
2003;21(2):241-7.
3.

Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea

and cardiovascular disease: an American Heart Association/American College of Cardiology
Foundation Scientific Statement from the American Heart Association Council for High Blood
Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke
Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol. 2008;52(8):686-717.
4.

Redline S, Yenokyan G, Gottlieb DJ, Shahar E, O'Connor GT, Resnick HE, et al.

Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir
Crit Care Med. 2010;182(2):269-77.
5.

Gottlieb DJ, Yenokyan G, Newman AB, O'Connor GT, Punjabi NM, Quan SF, et al.

Prospective study of obstructive sleep apnea and incident coronary heart disease and heart
failure: the sleep heart health study. Circulation. 2010;122(4):352-60.
6.

Mehra R, Redline S. Arrhythmia risk associated with sleep disordered breathing in

chronic heart failure. Curr Heart Fail Rep. 2014;11(1):88-97.
7.

Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE, et al. Sleep-

disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study.
Am J Epidemiol. 2004;160(6):521-30.
8.

Sulit L, Storfer-Isser A, Kirchner HL, Redline S. Differences in polysomnography

predictors for hypertension and impaired glucose tolerance. Sleep. 2006;29(6):777-83.
9.

Xie A, Skatrud JB, Puleo DS, Morgan BJ. Exposure to hypoxia produces long-lasting

sympathetic activation in humans. J Appl Physiol (1985). 2001;91(4):1555-62.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

10.

Fletcher EC, Lesske J, Qian W, Miller CC, 3rd, Unger T. Repetitive, episodic hypoxia

causes diurnal elevation of blood pressure in rats. Hypertension. 1992;19(6 Pt 1):555-61.
11.

Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea.

Physiol Rev. 2010;90(1):47-112.
12.

Roux F, D'Ambrosio C, Mohsenin V. Sleep-related breathing disorders and

cardiovascular disease. Am J Med. 2000;108(5):396-402.
13.

Caples SM, Garcia-Touchard A, Somers VK. Sleep-disordered breathing and

cardiovascular risk. Sleep. 2007;30(3):291-303.
14.

Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep

apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J.
2009;33(5):1195-205.
15.

de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, et al. Omentin

plasma levels and gene expression are decreased in obesity. Diabetes. 2007;56(6):1655-61.
16.

Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al.

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe
lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610-5.
17.

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-

1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated
in human diabetes. Nat Genet. 2003;34(3):267-73.
18.

Safronova O, Morita I. Transcriptome remodeling in hypoxic inflammation. J Dent Res.

2010;89(5):430-44.
19.

Ong CT, Corces VG. Enhancer function: new insights into the regulation of tissue-

specific gene expression. Nat Rev Genet. 2011;12(4):283-93.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

20.

Polotsky VY, Bevans-Fonti S, Grigoryev DN, Punjabi NM. Intermittent Hypoxia Alters

Gene Expression in Peripheral Blood Mononuclear Cells of Healthy Volunteers. PLoS One.
2015;10(12):e0144725.
21.

Schulz R, Hummel C, Heinemann S, Seeger W, Grimminger F. Serum levels of vascular

endothelial growth factor are elevated in patients with obstructive sleep apnea and severe
nighttime hypoxia. Am J Respir Crit Care Med. 2002;165(1):67-70.
22.

Khalyfa A, Capdevila OS, Buazza MO, Serpero LD, Kheirandish-Gozal L, Gozal D.

Genome-wide gene expression profiling in children with non-obese obstructive sleep apnea.
Sleep Med. 2009;10(1):75-86.
23.

Gharib SA, Seiger AN, Hayes AL, Mehra R, Patel SR. Treatment of obstructive sleep

apnea alters cancer-associated transcriptional signatures in circulating leukocytes. Sleep.
2014;37(4):709-14, 14A-14T.
24.

Perry JC, Guindalini C, Bittencourt L, Garbuio S, Mazzotti DR, Tufik S. Whole blood

hypoxia-related gene expression reveals novel pathways to obstructive sleep apnea in humans.
Respir Physiol Neurobiol. 2013;189(3):649-54.
25.

Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of

coronary heart disease in families. The Framingham offspring study. Am J Epidemiol.
1979;110(3):281-90.
26.

Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-

Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156(9):871-81.
27.

Gottlieb DJ, Punjabi NM, Mehra R, Patel SR, Quan SF, Babineau DC, et al. CPAP versus

oxygen in obstructive sleep apnea. N Engl J Med. 2014;370(24):2276-85.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

28.

Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, et al. Multi-

ethnic study of atherosclerosis: objectives and design. American journal of epidemiology.
2002;156(9):871-81.
29.

Chen X, Wang R, Zee P, Lutsey PL, Javaheri S, Alc√°ntara C, et al. Racial/ethnic

differences in sleep disturbances: the Multi-Ethnic Study of Atherosclerosis (MESA). Sleep.
2015;38(6):877-88.
30.

Liu Y, Ding J, Reynolds LM, Lohman K, Register TC, De La Fuente A, et al.

Methylomics of gene expression in human monocytes. Human molecular genetics.
2013;22(24):5065-74.
31.

Dawber TR, Meadors GF, Moore Jr FE. Epidemiological approaches to heart disease: the

Framingham Study. American Journal of Public Health and the Nations Health. 1951;41(3):27986.
32.

Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham

offspring study. Design and preliminary data. Preventive medicine. 1975;4(4):518-25.
33.

Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of

coronary heart disease in families: the Framingham Offspring Study. American journal of
epidemiology. 1979;110(3):281-90.
34.

Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O'Connor GT, et al. The Sleep Heart

Health Study: design, rationale, and methods. Sleep. 1997;20(12):1077-85.
35.

Redline S, Sanders MH, Lind BK, Quan SF, Iber C, Gottlieb DJ, et al. Methods for

obtaining and analyzing unattended polysomnography data for a multicenter study. Sleep Heart
Health Research Group. Sleep. 1998;21(7):759-67.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

36.

Quan SF, Howard BV, Iber C, Kiley JP, Nieto FJ, O'connor GT, et al. The sleep heart

health study: design, rationale, and methods. Sleep. 1997;20(12):1077-85.
37.

Joehanes R, Ying S, Huan T, Johnson AD, Raghavachari N, Wang R, et al. Gene

expression signatures of coronary heart disease. Arteriosclerosis, thrombosis, and vascular
biology. 2013;33(6):1418-26.
38.

Lin H, Yin X, Lunetta KL, Dupuis J, McManus DD, Lubitz SA, et al. Whole blood gene

expression and atrial fibrillation: the Framingham Heart Study. PLoS One. 2014;9(5):e96794.
39.

Strimmer K. fdrtool: a versatile R package for estimating local and tail area-based false

discovery rates. Bioinformatics. 2008;24(12):1461-2.
40.

Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-

analysis of gene expression microarray datasets. PLoS Med. 2008;5(9):e184.
41.

Sofer T, Heller R, Bogomolov M, Avery CL, Graff M, North KE, et al. A powerful

statistical framework for generalization testing in GWAS, with application to the HCHS/SOL.
Genet Epidemiol. 2017;41(3):251-8.
42.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al.

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide
expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.
43.

Isserlin R, Merico D, Voisin V, Bader GD. Enrichment Map - a Cytoscape app to

visualize and explore OMICs pathway enrichment results. F1000Res. 2014;3:141.
44.

Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, et al. Integration

of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2(10):236682.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

45.

Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity

of genetic association studies. Nat Genet. 2001;29(3):306-9.
46.

Hackenbeck T, Huber R, Schietke R, Knaup KX, Monti J, Wu X, et al. The GTPase

RAB20 is a HIF target with mitochondrial localization mediating apoptosis in hypoxia.
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 2011;1813(1):1-13.
47.

Gorgens SW, Benninghoff T, Eckardt K, Springer C, Chadt A, Melior A, et al. Hypoxia

in Combination With Muscle Contraction Improves Insulin Action and Glucose Metabolism in
Human Skeletal Muscle via the HIF-1alpha Pathway. Diabetes. 2017;66(11):2800-7.
48.

Aurora RN, Punjabi NM. Obstructive sleep apnoea and type 2 diabetes mellitus: a

bidirectional association. Lancet Respir Med. 2013;1(4):329-38.
49.

Levy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic

consequences. Eur Respir J. 2009;34(1):243-60.
50.

Olbryt M, Habryka A, Student S, Jarzab M, Tyszkiewicz T, Lisowska KM. Global gene

expression profiling in three tumor cell lines subjected to experimental cycling and chronic
hypoxia. PLoS One. 2014;9(8):e105104.
51.

Louis M, Punjabi NM. Effects of acute intermittent hypoxia on glucose metabolism in

awake healthy volunteers. J Appl Physiol (1985). 2009;106(5):1538-44.
52.

Oguchi ME, Etoh K, Fukuda M. Rab20, a novel Rab small GTPase that negatively

regulates neurite outgrowth of PC12 cells. Neuroscience Letters. 2018;662:324--30.
53.

Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE.

2007;2007(407):cm8.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

54.

Stelzer G, Rosen R, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The

GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analysis. Current
Protocols in Bioinformatics. 2016;54(1):1.30.1-1..3.
55.

Chaudhry MS, Karadimitris A. Role and regulation of CD1d in normal and pathological

B cells. J Immunol. 2014;193(10):4761-8.
56.

Gamaldo CE, Shaikh AK, McArthur JC. The sleep-immunity relationship. Neurol Clin.

2012;30(4):1313-43.
57.

Steiropoulos P, Kotsianidis I, Nena E, Tsara V, Gounari E, Hatzizisi O, et al. Long-term

effect of continuous positive airway pressure therapy on inflammation markers of patients with
obstructive sleep apnea syndrome. Sleep. 2009;32(4):537-43.
58.

Chen Q, Ross AC. Retinoic Acid Regulates CD1d Gene Expression at the Transcriptional

Level in Human and Rodent Monocytic Cells. Experimental Biology and Medicine.
2007;232(4):488‚Äì94.
59.

Hernandez-Jimenez E, Cubillos-Zapata C, Toledano V, Perez de Diego R, Fernandez-

Navarro I, Casitas R, et al. Monocytes inhibit NK activity via TGF-beta in patients with
obstructive sleep apnoea. Eur Respir J. 2017;49(6).
60.

Malmberg KJ, Carlsten M, Bjorklund A, Sohlberg E, Bryceson YT, Ljunggren HG.

Natural killer cell-mediated immunosurveillance of human cancer. Semin Immunol. 2017;31:209.
61.

Marshall NS, Wong KK, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea and 20-

year follow-up for all-cause mortality, stroke, and cancer incidence and mortality in the
Busselton Health Study cohort. J Clin Sleep Med. 2014;10(4):355-62.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

62.

Campos-Rodriguez F, Martinez-Garcia MA, Martinez M, Duran-Cantolla J, Pena Mde L,

Masdeu MJ, et al. Association between obstructive sleep apnea and cancer incidence in a large
multicenter Spanish cohort. Am J Respir Crit Care Med. 2013;187(1):99-105.
63.

Almendros I, Montserrat JM, Torres M, Bonsignore MR, Chimenti L, Navajas D, et al.

Obesity and intermittent hypoxia increase tumor growth in a mouse model of sleep apnea. Sleep
Med. 2012;13(10):1254-60.
64.

Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, et al. Preconditioning of

the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer
therapies. Cancer Res. 2006;66(24):11736-44.
65.

Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W. Review: hypoxia-

inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon
Cytokine Res. 2005;25(6):297-310.
66.

Iacobas S, Andrei Iacobas D. Effects of Chronic Intermittent Hypoxia on Cardiac

Rhythm Transcriptomic Networks Intermittent Hypoxia and Human Diseases. London:
Springer; 2012. p. 15‚Äì27.
67.

Nazmi AR, Ozorowski G, Pejic M, Whitelegge JP, Gerke V, Luecke H. N-terminal

acetylation of annexin A2 is required for S100A10 binding. Biol Chem. 2012;393(10):1141-50.
68.

Luo M, Flood EC, Almeida D, Yan L, Berlin DA, Heerdt PM, et al. Annexin A2 supports

pulmonary microvascular integrity by linking vascular endothelial cadherin and protein tyrosine
phosphatases. J Exp Med. 2017;214(9):2535-45.
69.

Rolfs A, Kvietikova I, Gassmann M, Wenger RH. Oxygen-regulated transferrin

expression is mediated by hypoxia-inducible factor-1. J Biol Chem. 1997;272(32):20055-62.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

70.

Lok CN, Ponka P. Identification of a hypoxia response element in the transferrin receptor

gene. J Biol Chem. 1999;274(34):24147-52.
71.

Mukhopadhyay CK, Mazumder B, Fox PL. Role of hypoxia-inducible factor-1 in

transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem.
2000;275(28):21048-54.
72.

Hofer T, Wenger RH, Kramer MF, Ferreira GC, Gassmann M. Hypoxic up-regulation of

erythroid 5-aminolevulinate synthase. Blood. 2003;101(1):348-50.
73.

Wang H, Cade BE, Sofer T, Sands SA, Chen H, Browning SR, et al. Admixture mapping

identifies novel loci for obstructive sleep apnea in Hispanic/Latino Americans. Hum Mol Genet.
2019;28(4):675-87.
74.

May AM, Mehra R. Obstructive sleep apnea: role of intermittent hypoxia and

inflammation. Semin Respir Crit Care Med. 2014;35(5):531-44.
75.

Yu C, Liu Y, Sun L, Wang D, Wang Y, Zhao S, et al. Chronic obstructive sleep apnea

promotes aortic remodeling in canines through miR-145/Smad3 signaling pathway. Oncotarget.
2017;8(23):37705-16.
76.

Korcarz CE, Peppard PE, Young TB, Chapman CB, Hla KM, Barnet JH, et al. Effects of

Obstructive Sleep Apnea and Obesity on Cardiac Remodeling: The Wisconsin Sleep Cohort
Study. Sleep. 2016;39(6):1187-95.
77.

Castro-Grattoni AL, Alvarez-Buve R, Torres M, Farre R, Montserrat JM, Dalmases M, et

al. Intermittent Hypoxia-Induced Cardiovascular Remodeling Is Reversed by Normoxia in a
Mouse Model of Sleep Apnea. Chest. 2016;149(6):1400-8.
78.

Ortmann B, Druker J, Rocha S. Cell cycle progression in response to oxygen levels. Cell

Mol Life Sci. 2014;71(18):3569-82.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

79.

Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible

factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol. 2003;23(1):359-69.
80.

Martinez-Garcia MA, Campos-Rodriguez F, Nagore E, Martorell A, Rodriguez-Peralto

JL, Riveiro-Falkenbach E, et al. Sleep-Disordered Breathing Is Independently Associated With
Increased Aggressiveness of Cutaneous Melanoma: A Multicenter Observational Study in 443
Patients. Chest. 2018;154(6):1348-58.
81.

Nieto FJ, Peppard PE, Young T, Finn L, Hla KM, Farre R. Sleep-disordered breathing

and cancer mortality: results from the Wisconsin Sleep Cohort Study. Am J Respir Crit Care
Med. 2012;186(2):190-4.
82.

Redline S, Schluchter MD, Larkin EK, Tishler PV. Predictors of Longitudinal Change in

Sleep-Disordered Breathing in a Nonclinic Population. Sleep. 2003;26(6):703-9.
83.

Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The Occurrence of Sleep-

Disordered Breathing among Middle-Aged Adults. New England Journal of Medicine.
1993;328:1230‚Äî5.

Acknowledgments: The authors thank the investigators, the staff and the participants of the
MESA study for their valuable contributions. A full list of participating MESA investigators and
institutions can be found at http://www.mesa-nhlbi.org. Funding: MESA and the MESA SHARe
project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI)
in collaboration with MESA investigators. Support for MESA is provided by contracts
HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168,

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and
DK063491. The MESA Epigenomics and Transcriptomics Study was funded by a National
Heart, Lung and Blood Institute grant (R01HL101250) to Wake Forest University Health
Sciences. The National Heart, Lung, and Blood Institute's (NHLBI's) FHS is supported by
National Institutes of Health Grant NO1-HC-25195. The SABRe CVD Initiative is funded by the
Division of Intramural Research, NHLBI, Bethesda, MD. The HeartBEAT study was funded by
the National Heart, Lung, and Blood Institute and others; HeartBEAT ClinicalTrials.gov
number, NCT01086800. Analysis of the HeartBEAT microarray data was funded by CTSA
award UL1-TR000157. This work was supported by NHLBI grant R35HL135818 to SR. HW
was supported by the Sleep Research Society Foundation Career Development Award 018-JP18. Author contributions: TS, DJG, and SAG conceptualized the association study. TS, RL, RJ,
HL, ACG, NK, BEC, JL, and SW performed statistical analysis and data harmonization. (data
collection; study design), all authors critically reviewed the manuscript. YL, JR, and SR
collected data and designed components of MESA and its gene expression study. DL collected
data and designed components of FOS and the SABRe CVD initiative which collected genes
expression data for FOS. RM, SRP, SFQ, SR, and DJG designed and executed the HeartBEAT
study, and DJG and AS designed its gene expression study. Competing interests: None. Data
and materials availability: all summary statistics from analysis reported in this manuscript are
provided in the Supplementary Material. Raw gene expression data for FOS are a part of SABRe
CVD study on dbGaP, with dbGaP study accession: phs000363.v17.p11. Data could could be
obtained by requesting authorized access to the Framingham Cohort Study phs000007 on dbGaP.
Gene expression data for MESA could be obtained using application to the MESA

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

https://www.mesa-nhlbi.org. Raw and processed gene expression data for HeartBEAT have been
deposited in the Gene Expression Omnibus (GEO), Series GSE133601.

Fig. 3. Network-based depiction of up-regulated gene sets in the analysis of gene expression
association with lower avgO2 (i.e., more severe SDB) in MESA. Gene sets with FDR q <
0.05 are shown. The sizes of the symbols correspond to the number of genes in the set.
Connectivity is based on overlapping genes among gene sets. Note that we did not
identify any gene sets that were down-regulated (FDR q < 0.05) in association with more
severe SDB.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Fig. 4. Network visualization of up- and down-regulated gene sets detected in the HeartBEAT
study. Gene sets with FDR q < 0.05 are shown. The sizes of the symbols correspond to the
number of genes in the set. Connectivity is based on overlapping genes between gene sets.

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 2. Genes identified in cross-replication analysis of MESA and FOS. Each row represents a
gene transcript that replicated between FOS and MESA. Discovery cohort is the study in which
the expression transcript was discovered (FDR q < 0.05). The identifiers corresponding to the
transcript within each gene expression platform (MESA probe, FOS probeset, HeartBEAT
Entrez Gene ID) are indicated. Discovery p is the original discovery p value, prior to multipletesting adjustment. Discovery FDR-value is the FDR q in the discovery study, after FDR
correction was applied to the discovery trait analysis. Replication p values are one-sided p values
in the follow-up cohorts, with directions based on the direction of association in the discovery
cohort. Cross-replication refers to FOS, when MESA is the discovery study, and to MESA, when
FOS is the discovery study.
Discovery

HeartBEAT
Entrez
Gene ID

Gene

ILMN_1708881 3525498

55647

ILMN_1678075 2892979

MESA
Probe

FOS
Probeset

Replication p
p

FDR q

Cross- Heart
Replication BEAT

Cohort

Trait

Sign

RAB20

FOS

avgO2

+

1.22E-07 2.17E-03

0.037

0.046

9425

CDYL

FOS

avgO2

-

6.80E-06 4.05E-02

0.044

0.229

ILMN_1702636 3779579

84617

TUBB6

MESA

minO2

-

2.02E-06 3.29E-03

0.032

0.908

ILMN_1699489 3779579

84617

TUBB6

MESA

minO2

-

1.47E-04 4.55E-02

0.032

0.908

ILMN_1717877 2448073

10625

IVNS1ABP

MESA

minO2

+

7.71E-06 9.12E-03

0.018

0.144

ILMN_2397750 2448073

10625

IVNS1ABP

MESA

minO2

+

2.64E-06 3.60E-03

0.018

0.144

ILMN_2235283 3954238

5594

MAPK1

MESA

minO2

-

1.43E-06 2.85E-03

0.037

0.830

ILMN_2058251 3236958

7431

VIM

MESA

avgO2

-

7.10E-05 4.72E-02

0.002

0.823

ILMN_1747775 3478457

2054

STX2

MESA

avgO2

+

1.39E-05 2.33E-02

0.008

0.568

ILMN_1656920 3554851

1396

CRIP1

MESA

minO2

-

7.97E-05 3.48E-02

0.037

0.198

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Table 3. Genes identified in the meta-analysis of FOS and MESA. Each row represents a gene
transcript that was identified (FDR q < 0.05) in the meta-analysis of FOS and MESA traitspecific results. The identifiers corresponding to the transcript within each gene expression
platform (MESA probe, FOS probeset, HeartBEAT Entrez Gene ID) are indicated. Meta-analysis
p values and FDR q values are the original and the FDR q values, respectively, computed on the
meta-analysis results of the relevant trait. HeartBEAT replication p values are one-sided p values
guided by the direction of association in the meta-analysis. Fig. 2 visualizes the effect sizes for
these transcripts in MESA and FOS for all investigated traits.

MESA
Probe

FOS
Probeset

HeartBEAT
Entrez
Gene ID

Gene

Trait

Sign

Meta
Analysis
p

Meta
Analysis
FDR q

HeartBEAT
replication p

ILMN_1708881

3525498

55647

RAB20

avgO2

+

1.93E-08

2.14E-04

0.046

ILMN_2381257

3802980

1824

DSC2

avgO2

-

3.26E-07

1.78E-03

0.999

ILMN_2397750

2448073

10625

IVNS1ABP

minO2

+

5.51E-07

5.56E-03

0.144

ILMN_1663119

3802980

1824

DSC2

avgO2

-

6.13E-07

2.27E-03

0.999

ILMN_2235283

3954238

5594

MAPK1

minO2

-

9.52E-07

5.56E-03

0.830

ILMN_1717877

2448073

10625

IVNS1ABP

minO2

+

1.54E-06

5.78E-03

0.144

ILMN_1702247

3591327

23582

CCNDBP1

AHI

+

1.99E-06

2.43E-02

0.944

ILMN_2046730

2435383

6281

S100A10

minO2

-

2.01E-06

5.87E-03

0.949

ILMN_1678075

2892979

9425

CDYL

avgO2

-

2.43E-06

5.44E-03

0.229

ILMN_1747775

3478457

2054

STX2

avgO2

+

4.34E-06

6.86E-03

0.568

ILMN_1796712

2435383

6281

S100A10

avgO2

-

4.86E-06

7.11E-03

0.949

ILMN_2058251

3236958

7431

VIM

avgO2

-

5.19E-06

7.25E-03

0.823

ILMN_1768110

2515933

51776

ZAK

avgO2

-

5.94E-06

7.53E-03

0.987

ILMN_2230902

2830946

1495

CTNNA1

avgO2

-

6.91E-06

7.82E-03

0.847

ILMN_1796712

2435383

6281

S100A10

minO2

-

7.35E-06

1.72E-02

0.949

ILMN_2046730

2435383

6281

S100A10

avgO2

-

7.96E-06

8.08E-03

0.949

ILMN_1765060

3536786

55030

FBXO34

avgO2

-

8.02E-06

8.09E-03

0.416

medRxiv preprint doi: https://doi.org/10.1101/19001727; this version posted August 12, 2019. The copyright holder for this preprint (which was
not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

MESA
Probe

FOS
Probeset

HeartBEAT
Entrez
Gene ID

Gene

Trait

Sign

Meta
Analysis
p

Meta
Analysis
FDR q

HeartBEAT
replication p

ILMN_1656920

3554851

1396

CRIP1

minO2

-

1.67E-05

3.23E-02

0.198

ILMN_1719433

2362157

912

CD1D

avgO2

+

1.85E-05

1.68E-02

0.002

ILMN_1755937

3627248

302

ANXA2

minO2

-

2.52E-05

4.21E-02

0.860

ILMN_1782538

3236958

7431

VIM

avgO2

-

3.41E-05

2.69E-02

0.823

ILMN_1717163

2940202

2162

F13A1

avgO2

-

4.85E-05

3.41E-02

0.846

ILMN_1810069

2525182

151195

CCNYL1

avgO2

-

5.38E-05

3.64E-02

0.950

ILMN_2329679

3955915

8459

TPST2

avgO2

-

6.91E-05

4.21E-02

0.122

ILMN_1769810

2628682

10550

ARL6IP5

avgO2

-

6.95E-05

4.22E-02

0.824

ILMN_1703926

3535780

5732

PTGER2

avgO2

-

7.56E-05

4.42E-02

0.516

ILMN_2366391

2410241

5052

PRDX1

avgO2

-

7.82E-05

4.50E-02

0.885

ILMN_1717877

2448073

10625

IVNS1ABP

avgO2

+

8.42E-05

4.67E-02

0.144

